Serono spinout grabs a $31M round for a pair of proof-of-concept Parkinson’s trials
Nearly 5 years ago, Prexton Therapeutics was the first new biotech to be spun out of the wreckage left behind after Merck KGaA decided to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
